Cegedim Relationship Management held its annual conference on trends in the life sciences industry last week.
In the rush toward customer engagement, can technology find the sweet spot?
Cegedim Relationship Management held its annual conference on trends in the life sciences industry last week, with two days of speakers and workshops focused on the interrelated themes of Transformation and Innovation. The central question: if the business of pharma is changing at warp speed, then what new strategies and practices are best poised to help companies maintain a competitive advantage?
On central display at the conference were the significant – and growing – capabilities of vendors like Cegedim in marshaling data points that reveal the identity, incentives and motivations of the customer.
Some of the more interesting factoids:
The overall conclusion is obvious: technology companies have the scale and scope to lead in solving the world’s health problems. On a strictly commercial level, pharma companies are coming to recognize that technology solutions eliminate many of the routine barriers they encounter in attempting to get closer to patients and the customer. The right agenda is to access patients directly where they seek information. And their platform of choice is increasingly digital. Instead of focusing on “pushing” out data compiled internally, the more important task is to come up with new ways to “pull it in,” through tools like social media. Likewise, the so-called conflict between print and online is a distraction. Companies must be agnostic; what matters is the principle of designing every communication from the perspective of the patient experience.
Finally, on the institutional side, one of the more interesting trends to emerge from the discussions is the growing visibility and clout of allied health professionals – a neglected target. Nurse practitioners, for example, are replacing physicians in many routine tasks and are now often authorized to be prescribers of medicines. In fact, while the position of the pharmaceutical industry is being upended by all the churn in the health care system, this is no less true for other players. One physician, speaking at a panel on how to increase value to customers, noted his profession faced a stark new reality, which he summarized as “No outcome? Then no income.”
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.